Apr 16 2010
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing potential best in class oncology and central nervous system (CNS) therapeutics, today announced that it will present pre-clinical data on its anticancer compound RX-8243 at the American Association for Cancer Research (AACR) 101st Annual Meeting, held in Washington, D.C., April 17-21, 2010, at the Walter E. Washington Convention Center.
“Characterization of a novel small molecule with potent anticancer activity”
These data on the anti-cancer activity of RX-8243 will be presented in a poster (abstract #3562) entitled, "Characterization of a novel small molecule with potent anticancer activity," on Tuesday, April 20, 2010, from 9:00 am - 12:00 pm EDT in Exhibit Hall A-C, Poster Section 24, during the "Experimental and Molecular Therapeutics" session.
Source Rexahn Pharmaceuticals, Inc.
www.rexahn.com
New study to test novel psychedelic compound as potential treatment for alcohol use disorder